Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
The Chosun Ilbo on MSN
Obesity treatments surpass Keytruda in global sales
Last year, sales of obesity treatments surpassed Keytruda, the immune anticancer drug that had long held the top sales ...
The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.
BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with ...
One day after a double-pronged loss in prostate and lung cancer, Merck & Co.’s immuno-oncology superstar Keytruda is bouncing back. In the phase 3 Keynote-671 study, Keytruda hit one of two primary ...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...
Pembrolizumab (Keytruda) elicited significantly better outcomes compared with ipilimumab (Yervoy) in a randomized phase 3 trial of patients with advanced melanoma. Keytruda (pembrolizumab) elicited ...
Keytruda’s first-line boost could come soon. Data from Keytruda’s first-line lung cancer study will be presented at the European Society of Medical Oncology meeting in October--the lung cancer study ...
For many lung cancer patients, Keytruda is a better initial treatment than chemotherapy, study finds
For many lung cancer patients, Keytruda is a better initial treatment than chemotherapy, study finds A large clinical trial shows that for many patients with the most common type of lung cancer, ...
RAHWAY, N.J. - Merck is officially adding an experimental flu prevention drug to its portfolio. The New Jersey-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback